logo

VIR

Vir Biotechnology·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

VIR Profile

Vir Biotechnology, Inc.

A biotech company developing innovative treatments for infectious diseases, including hepatitis B and COVID-19

Biological Technology
04/07/2016
10/11/2019
NASDAQ Stock Exchange
408
12-31
Common stock
1800 Owens Street, Suite 900, San Francisco, California 94158
--
Vir Biotechnology, Inc., was incorporated under the laws of the State of Delaware on April 7, 2016. The company is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious diseases, including virus-related diseases. The company aims to achieve this in two basic ways — first, by developing powerful antibody therapies, and second, by generating unique T-cell responses in vivo through a T-cell-based viral vector platform.